IP Library Granted Patent US 7,700,758
Granted Patent B2
US 7,700,758 · App. 10/622,240 · Granted Apr 20, 2010

Methods and compositions relating to gene silencing

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,700,758
App. No.
10/622,240
Granted
Apr 20, 2010
Kind
B2
Abstract

A method for obtaining a mixture of heterogenous short double-stranded RNA molecules suitable for use in gene silencing (hsiRNA) by subjecting large double-stranded RNA to enzymatic cleavage under specified conditions. The resulting mixture consistently includes enhanced representation of fragments having a size of 21-22 nucleotides absent any fractionation step. The fragments contain sequences that collectively span the entire length of the large double-stranded RNA from which they are derived. Double-stranded RNA with sequences that individually represent segments of a target mRNA may be analyzed using the methods described herein to identify the most active subset of hsiRNA fragments or individual siRNA fragments for achieving gene silencing for any gene or transcribed sequences. A method is additionally provided for preparing and cloning DNA encoding selected siRNA, hsiRNA mixtures or hairpin sequences to provide a continuous supply of a gene silencing reagent derived from any long double-stranded RNA.

Claims (21)

1. A method of producing a plurality of overlapping double stranded (ds) RNA fragments of a size in the range of about 15-30 nucleotides, comprising:

(a) digesting a preparation of large double-stranded RNA in a reaction mixture containing a divalent transition metal cation and a prokaryotic RNaseIII wherein the ratio of enzyme to substrate (w/w) is greater than or equal to about 0.25:1; and

(b) producing the plurality of overlapping dsRNA fragments of a size in the range of about 15-30 nucleotides.

2. A method according to claim 1 , wherein the plurality of overlapping fragments is the product of complete digestion of the preparation of large double-stranded RNA.

3. A method according to claim 1 , wherein the transition metal cation is manganese.

4. A method according to claim 3 , wherein the reaction mixture contains manganese ions at a concentration in the range of about 5-10 mM.

5. A method according to claim 3 , wherein the reaction mixture contains manganese ions at a concentration in the range of about 10-20 mM.

6. A method according to claim 1 , wherein the transition metal is selected from nickel, cobalt and cadmium.

7. A method according to claim 2 , wherein the complete digestion is achieved in less than 6 hours.

8. A method according to claim 2 , wherein the complete digestion—is achieved in less than 2 hours.

9. A method of silencing expression of a target gene, comprising:

introducing into a host cell, a plurality of fragments made according to claim 1 , wherein the nucleotide sequence for each fragment has a sequence that is complementary to the target gene.

10. A purified set of double-stranded RNA fragments, comprising a plurality of overlapping fragments of a size in the range of about 15-30 nucleotides, the fragments in the set collectively representing a substantial portion of a sequence of one or more large double-stranded RNAs from which the fragments are derived by in vitro cleavage with a purified enzyme, one strand of each of the large double-stranded RNA having a sequence complementary to part or all of a target RNA.

11. A set of fragments according to claim 10 , wherein the substantial portion is greater than about 50% of the sequence of the large double-stranded RNA.

12. A set of fragments according to claim 10 , wherein the substantial portion is greater than about 65% of the sequence of the large double-stranded RNA.

13. A set of fragments according to claim 10 , wherein more than about 30% of the RNA fragments have a fragment size of about 18-25 base pairs.

14. A set of fragments according to claim 10 , wherein at least one fragment and as many as 100% of fragments in the set are capable of causing cleaving the target RNA in a cell.

15. A set of fragments according to claim 14 , wherein at least about 50% of the fragments are capable of causing cleavage of the RNA.

16. A set of fragments according to claim 14 , wherein at least about 75% of the fragments are capable of causing cleavage of the mRNA.

17. A set of fragments according to claim 10 , capable of RNA silencing in vivo when introduced into a eukaryotic cell.

18. A purified set of double-stranded RNA fragments according to claim 10 , wherein the fragments bind specifically to mRNA to initiate cleavage of the mRNA.

Assignments (4)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Sep 20, 2023
From: BANK OF AMERICA, N.A. (AS SUCCESSOR-BY-MERGER WITH FLEET NATIONAL BANK)
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 064962/0066 →
RELEASE PREVIOUSLY RECORDED AT REEL/FRAME 014220/0763 Recorded Oct 22, 2004
From: FLEET NATIONAL BANK
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 015286/0792 →
SECURITY AGREEMENT Recorded Dec 30, 2003
From: NEW ENGLAND BIOLABS, INC.
To: FLEET NATIONAL BANK
Reel/Frame 014220/0763 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2003
From: TZERTZINIS, GEORGE; FEEHERY, GEORGE; TUCKEY, CORINNA; NOREN, CHRISTOPHER; MCREYNOLDS, LARRY
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 014316/0124 →